

## CURRENT REPORT 21/2024

June 3, 2024

### Conclusion of funding agreement with the Polish Agency for Enterprise Development

The Management Board of Ryvu Therapeutics S.A. with its registered office in Krakow, Poland ("Company") informs that on June 3, 2024, a funding agreement ("Agreement") was concluded with the Polish Agency for Enterprise Development ("PARP") for the Company's project titled: "ONCO Prime: new possibilities for personalised anti-cancer therapy based on patient-derived primary cell cultures, omics characterisation and functional assays" ("Project"). The Company informed about recommending the Project for funding in the current report 13/2024 dated March 27, 2024.

The Project is a significant component of the Company's plans in the area of the early pipeline. Its goal is to enable fighting cancer more effectively by creating the innovative ONCO Prime research platform, which addresses a number of current challenges and barriers in the development of new, personalized anti-cancer therapies.

The establishment of a new platform for discovering innovative therapeutic targets using unique patient-derived primary cancer cell cultures will open entirely new possibilities for identifying previously unknown targets, molecular classification of patients, and drug testing. The ONCO Prime platform will become a source of new cancer models with the highest translational potential, containing medical history, histopathological, genomic as well as transcriptomic data, enabling the correlation of clinical and molecular data.

- The total net value of the Project is: PLN 39 176 251.50;
- The maximum amount of the funding: PLN 26 339 315.38;
- The maximum Project implementation period: 56 months.

The funding granted in connection with the conclusion of the Agreement will reduce the use of the Company's own funds.

*Disclaimer: This English language translation has been prepared solely for the convenience of English-speaking readers. Despite all the efforts devoted to this translation, certain discrepancies, omissions or approximations may exist. In case of any differences between the Polish and the English versions, the Polish version shall prevail.*

*Ryvu Therapeutics S.A., its representatives and employees decline all responsibility in this regard.*

**Legal basis:** Article 17.1 of MAR

**Representatives of the Issuer:**

- Paweł Przewięźlikowski – President of the Management Board
- Kamil Sitarz – Member of the Management Board